The Department of Defense has released pre-announcements for the Hearing Restoration Research Program managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP) to allow investigators time to plan and develop ideas for submission to the anticipated FY19 funding opportunities.
Program focus areas for FY19:
- Develop or validate techniques/methods to assess or diagnose auditory dysfunction as related to synaptopathy, hidden hearing loss, and central auditory processing disorders. For example: diagnostic tests that help differentiate sensory, neural, synaptic, and central processing disorders; diagnostic tools for use in forward or remote deployed settings; treatments for the various types of damage that result in auditory dysfunction.
- Accelerate translation of biological regeneration/repair mechanisms into therapies that restore auditory function.
- Develop reliable in vitro human models for evaluating hearing restoration therapies.
The HRRP program is anticipated: Focused Research Award
- Independent investigators at all academic levels (or equivalent) are eligible to submit applications.
- Preproposal is required; application submission is by invitation only.
- Supports promising research that has the potential to make, or lead to, significant advancement in hearing restoration.
- Must address at least one of FY19 HRRP Focus Areas.
- It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
- Funding Level 1 requires preliminary data to support the rationale of the research idea and the investigating team’s expertise in the subject area. Maximum funding of $250,000 for direct costs (plus indirect costs) over a period of 2 years.
- Funding Level 2 requires preliminary data to support the feasibility of the proposed research strategy. May include a pilot clinical trial where limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials. If no pilot clinical trial is included, maximum funding of $1M for direct costs (plus indirect costs) over a period of 3 years. If the Pilot Clinical Trial Option is included: maximum funding of $1.25M for direct costs (plus indirect costs) over a period of 3 years.
Descriptions of each of the anticipated funding opportunities, eligibility, key mechanism elements, and funding can be found in the Program pre-announcement. FY19 pre-announcements can be found in the CDMRP home page features at https://cdmrp.army.mil.
Subsequent notifications will be sent when the program announcements/funding opportunities are released.
Filed Under: Funding Opportunities